EGB Advisors (2000-2004)
In-licensing of clinical-stage therapeutics. EGB was founded on our in-licensing or “drug hunting” practice.
Select Clients:
ChemGenex
(ASX: CXS)
CoTherix (acquired by Actelion, SW:ATLN)
DiObex
Kauffman Foundation
M. D. Anderson Cancer Center, Office of Technology
Commercialization
EGB Venture Development (2004-2008)
In 2004, EGB began to develop our own companies. Urigen (URGP.OB) was taken public in 2007 and we are planning to execute an Inverseon transaction in 2008.
Inverseon
Urigen Pharmaceuticals Inc.
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||||||||||
 |
 |
 |
 |
 |
|
||||||||||||
 |
|
||||||||||||||||
 |
|
||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||
 |
 |
 |
|
||||||||||||||
 |
|
||||||||||||||||
 |
 |
 |
|
||||||||||||||
 |
 |
 |
|
||||||||||||||
 |
|
||||||||||||||||
 |
|
||||||||||||||||